{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Asia/Hong_Kong", "exchangeTimezoneShortName": "HKT", "currency": "HKD", "market": "hk_market", "esgPopulated": false, "gmtOffSetMilliseconds": 28800000, "exchange": "HKG", "longName": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.", "shortName": "FUDANZHANGJIANG", "regularMarketPrice": 3.03, "regularMarketChangePercent": -1.9417458, "messageBoardId": "finmb_8288321", "marketState": "CLOSED", "fiftyTwoWeekHighChangePercent": -0.15363127, "fiftyTwoWeekLow": 2.51, "fiftyTwoWeekHigh": 3.58, "earningsTimestamp": 1551369540, "earningsTimestampStart": 1551369540, "earningsTimestampEnd": 1551369540, "trailingAnnualDividendRate": 0.07, "trailingPE": 20.199999, "trailingAnnualDividendYield": 0.022653723, "fiftyTwoWeekLowChange": 0.52, "fiftyTwoWeekLowChangePercent": 0.2071713, "fiftyTwoWeekRange": "2.51 - 3.58", "fiftyTwoWeekHighChange": -0.54999995, "epsTrailingTwelveMonths": 0.15, "epsForward": 0.28, "sharesOutstanding": 326000000, "bookValue": 2.202, "fiftyDayAverage": 3.2174, "fiftyDayAverageChange": -0.1874001, "fiftyDayAverageChangePercent": -0.05824582, "twoHundredDayAverage": 3.1048, "twoHundredDayAverageChange": -0.074800014, "twoHundredDayAverageChangePercent": -0.024091734, "marketCap": 8367102464, "forwardPE": 10.821428, "priceToBook": 1.3760219, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "prevName": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.", "nameChangeDate": "2023-05-12", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1029202200000, "priceHint": 3, "regularMarketChange": -0.059999943, "regularMarketTime": 1683878916, "regularMarketDayHigh": 3.09, "regularMarketDayRange": "3.03 - 3.09", "regularMarketDayLow": 3.03, "regularMarketVolume": 230000, "regularMarketPreviousClose": 3.09, "bid": 3.03, "ask": 3.07, "bidSize": 0, "askSize": 0, "fullExchangeName": "HKSE", "financialCurrency": "CNY", "regularMarketOpen": 3.07, "averageDailyVolume3Month": 280492, "averageDailyVolume10Day": 298800, "symbol": "1349.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Zhangjiang Hi-Tech Park", "address2": "No. 308 Cailun Road Pudong", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 21 5895 3355", "fax": "86 21 5855 3990", "website": "https://www.fd-zj.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.", "fullTimeEmployees": 910, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hai Bo  Wang", "age": 62, "title": "Co-Founder, Chairman & GM", "yearBorn": 1960, "fiscalYear": 2021, "totalPay": {"raw": 469663, "fmt": "469.66k", "longFmt": "469,663"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Da Jun  Zhao", "age": 52, "title": "Co-Founder, Deputy GM & Exec. Director", "yearBorn": 1970, "fiscalYear": 2021, "totalPay": {"raw": 378472, "fmt": "378.47k", "longFmt": "378,472"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Yong  Su", "age": 58, "title": "Deputy GM & Exec. Director", "yearBorn": 1964, "fiscalYear": 2021, "totalPay": {"raw": 374865, "fmt": "374.87k", "longFmt": "374,865"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jun  Li", "age": 54, "title": "Co-Founder & Deputy GM", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Xue  Yan FCCA, HKICPA, ACCA, CICPA, CIA", "age": 40, "title": "CFO & Company Sec.", "yearBorn": 1982, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Dai Qing  Yu", "age": 49, "title": "Quality Director & Employee Representative Supervisor", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}